Abciximab (ReoPro) is a glycoprotein IIb/IIIa inhibitor that does what?

Abciximab (ReoPro) is a glycoprotein IIb/IIIa inhibitor that does what?

• A. Irreversibly prevents platelet aggregation for the life of the platelet
• B. Reversibly inhibits platelet aggregation
• C. Directly inhibits thrombin
• D. Activates plasminogen

Answer: (A)

Abciximab blocks the final common pathway of platelet aggregation by occupying the glycoprotein IIb/IIIa receptor on activated platelets, preventing fibrinogen (and von Willebrand factor) from cross-linking platelets. This binding is essentially irreversible, so the antiplatelet effect lasts for the platelet’s entire lifespan, roughly 7–10 days, until new platelets are produced. Clinically, this provides strong anti-thrombotic protection during procedures like PCI but increases bleeding risk and may require platelet transfusion if reversal is needed. It does not directly inhibit thrombin or activate plasminogen, which is why those other options aren’t correct.

Abciximab blocks the final common pathway of platelet aggregation by occupying the glycoprotein IIb/IIIa receptor on activated platelets, preventing fibrinogen (and von Willebrand factor) from cross-linking platelets. This binding is essentially irreversible, so the antiplatelet effect lasts for the platelet’s entire lifespan, roughly 7–10 days, until new platelets are produced. Clinically, this provides strong anti-thrombotic protection during procedures like PCI but increases bleeding risk and may require platelet transfusion if reversal is needed. It does not directly inhibit thrombin or activate plasminogen, which is why those other options aren’t correct.